[{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Aig Investments","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series C Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Aig Investments","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Aig Investments"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sarissa Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series E Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sarissa Capital","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sarissa Capital"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Immediate Release","sponsorNew":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"Lyndra Therapeutics \/ Sun Pharmaceutical Industries Limited"}]

Find Clinical Drug Pipeline Developments & Deals by Lyndra Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : LYN-005 (oral weekly risperidone), is being evaluated in phase 3 clinical trials for the treatment of people living with schizophrenia and bipolar 1 disorder.

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 01, 2024

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The financing will obtain access to technology for certain compounds while developing novel pharmaceutical delivery systems, including LYN-005 (risperidone) for schizophrenia and bipolar I disorder.

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 01, 2024

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : $30.0 million

                          Deal Type : Financing

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The net proceeds will support the development of Lyndra’s pipeline, including oral weekly LYN-005 (risperidone), which is near completion of a pivotal phase 3 study and is being developed for the treatment of people living with schizophrenia and bipola...

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 25, 2023

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Sarissa Capital

                          Deal Size : $101.0 million

                          Deal Type : Series E Financing

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Oral weekly LYN-005 (risperidone) is a serotonin and norepinephrine reuptake inhibitor and is being developed for the treatment of people living with schizophrenia and bipolar I disorder.

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 05, 2023

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.

                          Product Name : LYN-163

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 06, 2022

                          Lead Product(s) : Ivermectin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD).

                          Product Name : LYN-014

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2021

                          Lead Product(s) : Levomethadone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Data demonstrate LYN-013 delivered sustained buprenorphine drug levels over one-week dosing period and showed sustained suppression of opioid self-administration in an animal model.

                          Product Name : LYN-013

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          June 25, 2021

                          Lead Product(s) : Buprenorphine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : LYN-005 is Lyndra's oral, ultra-long-acting, extended-release risperidone capsule, in development for the weekly treatment of schizophrenia. Funding will advance Lyndra’s lead product candidate into pivotal trials as the Company prepares for commercial...

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 24, 2021

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Aig Investments

                          Deal Size : $60.5 million

                          Deal Type : Series C Financing

                          blank

                          09

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : LYN-014 is designed to address a critical unmet need for people with opioid use disorder and provide consistent target therapeutic levels of levomethadone over the course of an entire week from a single, once-weekly oral capsule.

                          Product Name : LYN-014

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 05, 2021

                          Lead Product(s) : Levomethadone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Data demonstrate LYN-005 quickly reaches therapeutic levels in patients, provides sustained risperidone drug levels for repeat one-week dosing intervals and reduces peak drug exposure.

                          Product Name : LYN-005

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 18, 2021

                          Lead Product(s) : Risperidone

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank